Secukinumab Treatment of Plaque Psoriasis Shows Early Improvement in DLQI Response - Results of a Phase II Regimen-finding Trial

Overview

Journal J Eur Acad Dermatol Venereol

Specialty Infectious Diseases

Date 2015 Dec 15

PMID 26660143

Citations 9

Authors

M Augustin

S Abeysinghe

U Mallya

A Qureshi

N Roskell

D McBride

C Papavassillis

J Gelfand

Affiliations

Soon will be listed here.

Abstract

Background: The social stigma and chronicity of psoriasis significantly affect health-related quality of life (HRQoL).

Objective: We examined the effect of three regimens of secukinumab on HRQoL in moderate to severe psoriasis patients.

Methods: Twelve-week data from a phase II, randomized, double-blind, placebo-controlled, regimen-finding study evaluated HRQoL, measured by the Dermatology Life Quality Index (DLQI). Secukinumab or placebo was administered subcutaneously in three treatment regimens: single (baseline only), monthly (baseline, weeks 4, 8) and early (baseline, weeks 1, 2, 4). Differences among regimens were assessed with logistic regression models and Fisher's exact test.

Results: Patients (n = 404) were randomized to single (baseline) treatment regimen, n = 66; monthly, (baseline, weeks 4 and 8), n = 138; early, (baseline, weeks 1, 2, 4), n = 133; and placebo, n = 67. DLQI response was significantly higher in early, monthly and single regimens than in placebo regimen (40.8%, 33.6% and 13.1% vs. 1.6%, respectively; P < 0.001 for all).

Conclusion: Moderate to severe psoriasis patients receiving monthly and early treatment with secukinumab demonstrated improved HRQoL compared with placebo.

Citing Articles

Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence.

Malagoli P, Dapavo P, Amerio P, Atzori L, Balato A, Bardazzi F Dermatol Ther (Heidelb). 2024; 14(10):2739-2757.

PMID: 39316358 PMC: 11480300. DOI: 10.1007/s13555-024-01255-4.

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C Cochrane Database Syst Rev. 2023; 7:CD011535.

PMID: 37436070 PMC: 10337265. DOI: 10.1002/14651858.CD011535.pub6.

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C Cochrane Database Syst Rev. 2022; 5:CD011535.

PMID: 35603936 PMC: 9125768. DOI: 10.1002/14651858.CD011535.pub5.

The Impact of Hypertension, Diabetes, Lipid Disorders, Overweight/Obesity and Nicotine Dependence on Health-Related Quality of Life and Psoriasis Severity in Psoriatic Patients Receiving Systemic Conventional and Biological Treatment.

Karpinska-Mirecka A, Bartosinska J, Krasowska D Int J Environ Res Public Health. 2021; 18(24).

PMID: 34948777 PMC: 8701055. DOI: 10.3390/ijerph182413167.

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C Cochrane Database Syst Rev. 2021; 4:CD011535.

PMID: 33871055 PMC: 8408312. DOI: 10.1002/14651858.CD011535.pub4.

References

Norlin J, Carlsson K, Persson U, Schmitt-Egenolf M . Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. Br J Dermatol. 2011; 166(4):797-802. DOI: 10.1111/j.1365-2133.2011.10778.x. View

Spandonaro F, Altomare G, Berardesca E, Calzavara-Pinton P, Chimenti S, Girolomoni G . Health-related quality of life in psoriasis: an analysis of Psocare project patients. G Ital Dermatol Venereol. 2011; 146(3):169-77. View

Cozzani E, Borrini V, Pennella A, Burlando M, Cardo P, Rebora A . The quality of life in Italian psoriatic patients treated with biological drugs. G Ital Dermatol Venereol. 2010; 145(6):709-12. View

Hueber W, Patel D, Dryja T, Wright A, Koroleva I, Bruin G . Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010; 2(52):52ra72. DOI: 10.1126/scitranslmed.3001107. View

Basra M, Fenech R, Gatt R, Salek M, Finlay A . The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008; 159(5):997-1035. DOI: 10.1111/j.1365-2133.2008.08832.x. View

Revicki D, Menter A, Feldman S, Kimel M, Harnam N, Willian M . Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes. 2008; 6:75. PMC: 2579425. DOI: 10.1186/1477-7525-6-75. View

Kimball A, Gladman D, Gelfand J, Gordon K, Horn E, Korman N . National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008; 58(6):1031-42. PMC: 3716382. DOI: 10.1016/j.jaad.2008.01.006. View

Augustin M, Kruger K, Radtke M, Schwippl I, Reich K . Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology. 2008; 216(4):366-72. DOI: 10.1159/000119415. View

Schmitt J, Meurer M, Klon M, Frick K . Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br J Dermatol. 2007; 158(2):351-9. DOI: 10.1111/j.1365-2133.2007.08354.x. View

10.

Griffiths C, Barker J . Pathogenesis and clinical features of psoriasis. Lancet. 2007; 370(9583):263-271. DOI: 10.1016/S0140-6736(07)61128-3. View

11.

Shikiar R, Heffernan M, Langley R, Willian M, Okun M, Revicki D . Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat. 2007; 18(1):25-31. DOI: 10.1080/09546630601121060. View

12.

Shikiar R, Willian M, Okun M, Thompson C, Revicki D . The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes. 2006; 4:71. PMC: 1615869. DOI: 10.1186/1477-7525-4-71. View

13.

Reich K, Nestle F, Papp K, Ortonne J, Wu Y, Bala M . Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol. 2006; 154(6):1161-8. DOI: 10.1111/j.1365-2133.2006.07237.x. View

14.

Hongbo Y, Thomas C, Harrison M, Salek M, Finlay A . Translating the science of quality of life into practice: What do dermatology life quality index scores mean?. J Invest Dermatol. 2005; 125(4):659-64. DOI: 10.1111/j.0022-202X.2005.23621.x. View

15.

Rapp S, Feldman S, Exum M, Fleischer Jr A, Reboussin D . Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999; 41(3 Pt 1):401-7. DOI: 10.1016/s0190-9622(99)70112-x. View

16.

Finlay A, Khan G . Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19(3):210-6. DOI: 10.1111/j.1365-2230.1994.tb01167.x. View

17.

FREDRIKSSON T, Pettersson U . Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978; 157(4):238-44. DOI: 10.1159/000250839. View

18.

Schiffner R, Schiffner-Rohe J, Gerstenhauer M, Hofstadter F, Landthaler M, Stolz W . Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients?. Br J Dermatol. 2003; 148(6):1153-60. DOI: 10.1046/j.1365-2133.2003.05156.x. View

19.

Raychaudhuri S, Farber E . The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001; 15(1):16-7. DOI: 10.1046/j.1468-3083.2001.00192.x. View

20.

Krueger G, Koo J, Lebwohl M, Menter A, Stern R, Rolstad T . The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001; 137(3):280-4. View